← Back to IPO List

Attovia Therapeutics

Last updated: August 2, 2026
Ticker
ATTO
Exchange
NYSE
IPO Date
Pending
Price Range
$15.00 - $17.00
Deal Size
$200 million

Company Snapshot

Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation biotherapeutics for immune-mediated diseases with significant unmet needs. The company utilizes its proprietary ATTOBODY biologics platform to create innovative treatments that target commercially validated pathways. Their lead product candidate, ATTO-1310, is currently in a Phase 1 clinical trial for chronic pruritus and high-itch atopic dermatitis.

Founded
2022

Key Financials

Metric202520242023
Revenue$1.4M$300.0KNot provided
YoY Growth+366.7%--
Adjusted Net Loss-$60.6M-$39.8MNot provided
Margin %-4328.6%-13266.7%-

Balance Sheet

Cash & Equivalents
$40.2M

Implied Valuation at Midpoint

Market Cap
$616M
P/S Ratio
440.3x

Based on price range midpoint and most recent fiscal year data.

S-1 Highlights

Market & Competition

The company operates within the biopharmaceutical industry, targeting immune-mediated diseases. Attovia Therapeutics competes with established companies in the sector, though specific competitor names are not mentioned in the filing.

Use of Proceeds

Proceeds from the IPO are expected to be used to fund clinical trials and support the development of their product candidates.

Key Risk Factors

  • ●The company relies on third parties for conducting clinical trials, and any failure by these parties could delay their development programs.
  • ●Regulatory approval processes are highly uncertain, and the company may face challenges in obtaining necessary approvals for their product candidates.

Deal Structure

Primary Shares
12,500,000 shares
Shares Outstanding
38,529,017 shares
Post-IPO Float
32.4%
Lock-up
180 days
Lead Underwriters
Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, LifeSci Capital

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.